CN101528259B - 结合cxcr4的人类抗体及其用途 - Google Patents

结合cxcr4的人类抗体及其用途 Download PDF

Info

Publication number
CN101528259B
CN101528259B CN200780040511.4A CN200780040511A CN101528259B CN 101528259 B CN101528259 B CN 101528259B CN 200780040511 A CN200780040511 A CN 200780040511A CN 101528259 B CN101528259 B CN 101528259B
Authority
CN
China
Prior art keywords
cxcr4
seq
antibody
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780040511.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101528259A (zh
Inventor
M·库恩
P·布拉姆斯
D·M·塔纳玛奇
A·科曼
J·M·卡达里尔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39402166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101528259(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex LLC filed Critical Medarex LLC
Priority to CN201410083654.5A priority Critical patent/CN103897058B/zh
Publication of CN101528259A publication Critical patent/CN101528259A/zh
Application granted granted Critical
Publication of CN101528259B publication Critical patent/CN101528259B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
CN200780040511.4A 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途 Expired - Fee Related CN101528259B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410083654.5A CN103897058B (zh) 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82785106P 2006-10-02 2006-10-02
US60/827,851 2006-10-02
PCT/US2007/021152 WO2008060367A2 (en) 2006-10-02 2007-10-01 Human antibodies that bind cxcr4 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410083654.5A Division CN103897058B (zh) 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途

Publications (2)

Publication Number Publication Date
CN101528259A CN101528259A (zh) 2009-09-09
CN101528259B true CN101528259B (zh) 2014-04-09

Family

ID=39402166

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780040511.4A Expired - Fee Related CN101528259B (zh) 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途
CN201410083654.5A Expired - Fee Related CN103897058B (zh) 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410083654.5A Expired - Fee Related CN103897058B (zh) 2006-10-02 2007-10-01 结合cxcr4的人类抗体及其用途

Country Status (29)

Country Link
US (3) US8450464B2 (cg-RX-API-DMAC7.html)
EP (2) EP2066351B1 (cg-RX-API-DMAC7.html)
JP (4) JP5417175B2 (cg-RX-API-DMAC7.html)
KR (3) KR20170123712A (cg-RX-API-DMAC7.html)
CN (2) CN101528259B (cg-RX-API-DMAC7.html)
AR (2) AR063086A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007320024B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718197A2 (cg-RX-API-DMAC7.html)
CA (1) CA2665239A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002835A1 (cg-RX-API-DMAC7.html)
CY (2) CY1117036T1 (cg-RX-API-DMAC7.html)
DK (2) DK2066351T3 (cg-RX-API-DMAC7.html)
EA (1) EA018836B1 (cg-RX-API-DMAC7.html)
ES (2) ES2625798T3 (cg-RX-API-DMAC7.html)
HU (2) HUE033630T2 (cg-RX-API-DMAC7.html)
IL (1) IL197831A (cg-RX-API-DMAC7.html)
LT (1) LT2486941T (cg-RX-API-DMAC7.html)
ME (1) ME02269B (cg-RX-API-DMAC7.html)
MX (1) MX2009003306A (cg-RX-API-DMAC7.html)
NO (1) NO345287B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ575924A (cg-RX-API-DMAC7.html)
PL (2) PL2486941T3 (cg-RX-API-DMAC7.html)
PT (2) PT2066351E (cg-RX-API-DMAC7.html)
RS (2) RS54424B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201608268RA (cg-RX-API-DMAC7.html)
SI (2) SI2486941T1 (cg-RX-API-DMAC7.html)
TW (2) TWI522366B (cg-RX-API-DMAC7.html)
WO (1) WO2008060367A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902256B (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007276435C1 (en) 2006-07-18 2013-06-13 TME Pharma AG SDF-I binding nucleic acids
HUE033630T2 (en) * 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
LT2190991T (lt) * 2007-08-06 2020-02-10 Noxxon Pharma Ag Sdf-1 surišančios nukleorūgštys ir jų panaudojimas
CN102027015A (zh) * 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
DK2548950T3 (en) 2009-06-05 2017-12-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
EP2486056A1 (en) * 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
LT2499161T (lt) * 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
WO2011083141A2 (en) * 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2011161266A1 (en) * 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
EP2726634B1 (en) 2011-07-01 2017-02-22 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
RS58102B1 (sr) * 2011-11-09 2019-02-28 Bristol Myers Squibb Co Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom
PE20151410A1 (es) * 2013-02-26 2015-09-18 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
RU2678421C2 (ru) 2013-06-28 2019-01-28 Экс-Боди, Инк. Обнаружение антигена-мишени, фенотипический скрининг и его применение для идентификации специфичных эпитопов-мишеней клеток-мишеней
BR112016002008B1 (pt) * 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
US10526660B2 (en) * 2013-09-12 2020-01-07 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
EP3779440A1 (en) * 2013-09-23 2021-02-17 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
ES2742079T3 (es) * 2013-11-06 2020-02-13 Bristol Myers Squibb Co Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
CA2930326C (en) 2013-12-06 2022-09-06 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
PL3094353T3 (pl) 2014-01-15 2020-09-07 Medimmune, Llc Przeciwciała swoiste pod kątem RSV i ich funkcjonalne części
JP2017527615A (ja) * 2014-09-02 2017-09-21 シーダーズ−サイナイ メディカル センター 線維化疾患及び癌を治療するための組成物及び方法
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
CN114478773A (zh) * 2015-01-09 2022-05-13 阿达尔塔有限公司 Cxcr4结合分子
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
RU2719033C2 (ru) 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
JP2018516969A (ja) * 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
EP3394096A1 (en) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
WO2017196598A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
CN109219620B (zh) 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3500574B1 (en) 2016-08-19 2021-11-24 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
ES2973728T3 (es) 2018-03-13 2024-06-24 Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
MX2020012674A (es) 2018-05-29 2021-02-09 Bristol Myers Squibb Co Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
JP7447388B2 (ja) 2018-07-13 2024-03-12 ナンジン レジェンド バイオテック カンパニー，リミテッド 感染性疾患の治療のための共受容体システム
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
DK3886914T3 (da) 2018-11-30 2023-07-03 Bristol Myers Squibb Co Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
CN113544155A (zh) 2018-12-12 2021-10-22 百时美施贵宝公司 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US20230151104A1 (en) * 2020-04-23 2023-05-18 Remd Biotherapeutics, Inc. Chemokine receptor 4 (cxcr4) antagonist antibodies
WO2021222313A1 (en) 2020-04-27 2021-11-04 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN117003876B (zh) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206909A1 (en) * 2002-02-08 2003-11-06 Shaobing Hua Human monoclonal antibodies against membrane proteins
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU665221B2 (en) 1991-12-02 1995-12-21 Cambridge Antibody Technology Limited Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2191016T3 (es) 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
CA2117953C (en) 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
WO1995018634A1 (en) 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6114120A (en) 1995-05-03 2000-09-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US5840598A (en) 1997-08-14 1998-11-24 Micron Technology, Inc. LOC semiconductor assembled with room temperature adhesive
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
CN1325517C (zh) 1998-07-21 2007-07-11 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
CA2395882C (en) 1999-12-30 2012-07-17 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US20040001822A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2446968C (en) 2001-05-11 2012-07-03 Kirin Beer Kabushiki Kaisha Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
JP2008522583A (ja) * 2002-06-14 2008-07-03 セントカー・インコーポレーテツド 修飾“ｓ”抗体
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
CN103709250B (zh) 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2004050032A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies against drugs of abuse
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
US7456264B2 (en) 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
AR051805A1 (es) * 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
DK2620450T3 (en) 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
HUE033630T2 (en) * 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
RS58102B1 (sr) * 2011-11-09 2019-02-28 Bristol Myers Squibb Co Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom
ES2742079T3 (es) * 2013-11-06 2020-02-13 Bristol Myers Squibb Co Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206909A1 (en) * 2002-02-08 2003-11-06 Shaobing Hua Human monoclonal antibodies against membrane proteins
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof

Also Published As

Publication number Publication date
JP6496673B2 (ja) 2019-04-03
EP2486941B1 (en) 2017-03-15
CN103897058B (zh) 2018-06-15
AU2007320024B2 (en) 2012-11-08
LT2486941T (lt) 2017-06-12
ZA200902256B (en) 2019-02-27
PL2066351T3 (pl) 2016-02-29
CA2665239A1 (en) 2008-05-22
NO345287B1 (no) 2020-11-30
NO20091283L (no) 2009-04-24
SI2486941T1 (sl) 2017-08-31
KR101722261B1 (ko) 2017-04-03
NZ575924A (en) 2012-05-25
EA018836B1 (ru) 2013-11-29
TW200831535A (en) 2008-08-01
KR20150065959A (ko) 2015-06-15
AU2007320024A1 (en) 2008-05-22
KR20090064589A (ko) 2009-06-19
EP2066351B1 (en) 2015-09-09
EP2486941A1 (en) 2012-08-15
JP2013227339A (ja) 2013-11-07
JP5417175B2 (ja) 2014-02-12
PT2066351E (pt) 2015-11-30
IL197831A (en) 2017-01-31
EP2066351A2 (en) 2009-06-10
IL197831A0 (en) 2011-08-01
CY1117036T1 (el) 2017-04-05
JP6097650B2 (ja) 2017-03-15
HK1131904A1 (en) 2010-02-12
ES2553553T3 (es) 2015-12-10
BRPI0718197A2 (pt) 2014-09-30
SG178712A1 (en) 2012-03-29
CL2007002835A1 (es) 2008-05-30
CY1118949T1 (el) 2018-01-10
TWI522366B (zh) 2016-02-21
US20130251729A1 (en) 2013-09-26
AR063086A1 (es) 2008-12-23
SI2066351T1 (sl) 2016-02-29
AR113225A2 (es) 2020-02-19
HUE033630T2 (en) 2017-12-28
PL2486941T3 (pl) 2017-08-31
RS54424B1 (sr) 2016-04-28
MX2009003306A (es) 2009-04-23
JP2010505830A (ja) 2010-02-25
WO2008060367A3 (en) 2008-11-06
HUE027165T2 (en) 2016-08-29
KR20170123712A (ko) 2017-11-08
US11312777B2 (en) 2022-04-26
TW201604208A (zh) 2016-02-01
ES2625798T3 (es) 2017-07-20
SG10201608268RA (en) 2016-11-29
CN103897058A (zh) 2014-07-02
EA200900424A1 (ru) 2009-08-28
JP2019054798A (ja) 2019-04-11
RS55740B1 (sr) 2017-07-31
CN101528259A (zh) 2009-09-09
ME02269B (me) 2016-04-28
TWI592425B (zh) 2017-07-21
WO2008060367A2 (en) 2008-05-22
JP2016105719A (ja) 2016-06-16
US20190031763A1 (en) 2019-01-31
DK2486941T3 (en) 2017-06-26
DK2066351T3 (en) 2015-12-14
US10106615B2 (en) 2018-10-23
PT2486941T (pt) 2017-05-30
US20100104508A1 (en) 2010-04-29
US8450464B2 (en) 2013-05-28
WO2008060367A9 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
CN101528259B (zh) 结合cxcr4的人类抗体及其用途
CN101370830A (zh) 抗cd70的人单克隆抗体
HK1174828A (en) Human antibodies that bind cxcr4 and uses thereof
HK1174828B (en) Human antibodies that bind cxcr4 and uses thereof
HK1131904B (en) Human antibodies that bind cxcr4 and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MEDAREX INC.

Free format text: FORMER OWNER: MEDAREX, INC.

Effective date: 20130710

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130710

Address after: New jersey, USA

Applicant after: MEDAREX, Inc.

Address before: New jersey, USA

Applicant before: Medarex, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: PCT international application published data

Correct: WO2008/O6O367 E N 2008.05.22

False: WO2008/O6O367 E N 2008.07.10

Number: 15

Volume: 30

CI03 Correction of invention patent

Correction item: PCT international application published data

Correct: WO2008/O6O367 E N 2008.05.22

False: WO2008/O6O367 E N 2008.07.10

Number: 15

Page: The title page

Volume: 30

ERR Gazette correction

Free format text: CORRECT: PCT INTERNATIONAL APPLICATION PUBLISHED DATA; FROM: WO2008 6O367 EN 2008 7 0 TO: WO2008 6O367 EN 2008 5 2

RECT Rectification
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161019

Address after: New jersey, USA

Patentee after: E. R. SQUIBB & SONS, LLC

Address before: New jersey, USA

Patentee before: MEDAREX, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409